Descriptive statistics n, mean (SD)
|
HADS Anxiety
|
Pre-treatment
|
95
|
13.44 (3.67)
|
96
|
12.90 (4.02)
| | |
Post-treatment
|
73
|
8.56 (5.00)
|
73
|
11.08 (4.90)
|
− 2.41 (− 4.04 to − 0.77)
|
0.004
|
Follow-up
|
62
|
8.17 (5.12)
|
67
|
10.12 (4.79)
|
− 1.69 (− 3.41 to 0.02)
|
0.05
|
HADS Depression
|
Pre-treatment
|
95
|
12.18 (3.99)
|
96
|
10.80 (3.72)
| | |
Post-treatment
|
73
|
8.16 (4.17)
|
73
|
9.92 (4.37)
|
− 1.85 (− 3.29 to − 0.41)
|
0.01
|
Follow-up
|
62
|
8.04 (4.89)
|
67
|
9.67 (3.94)
|
− 1.30 (− 2.81 to 0.21)
|
0.09
|
HADS
|
Pre-treatment
|
95
|
25.62 (6.61)
|
96
|
23.70 (6.07)
| | |
Post-treatment
|
73
|
16.72 (8.44)
|
73
|
21.00 (7.88)
|
− 4.35 (− 6.99 to − 1.71)
|
0.002
|
Follow-up
|
62
|
16.23 (8.81)
|
67
|
19.79 (7.77)
|
− 3.10 (− 5.76 to − 0.26)
|
0.03
|
WHODAS
|
Pre-treatment
|
96
|
33.41 (7.17)
|
96
|
32.77 (7.77)
| | |
Post-treatment
|
74
|
25.20 (8.97)
|
74
|
28.41 (8.19)
|
− 3.16 (− 6.38 to − 0.85)
|
0.01
|
Follow-up
|
62
|
22.94 (9.73)
|
67
|
27.37 (8.36)
|
− 4.35 (− 7.24 to − 1.45)
|
0.004
|
PCL
|
Pre-treatment
|
96
|
49.78 (13.99)
|
96
|
49.86 (13.66)
| | |
Post-treatment
|
61
|
39.90 (15.89)
|
63
|
42.35 (15.73)
|
− 2.69 (− 8.08 to 2.70)
|
0.32
|
Follow-up
|
61
|
32.93 (14.21)
|
64
|
39.08 (15.75)
|
− 5.39 (− 10.76 to − 0.02)
|
0.05
|
PHQ
|
Pre-treatment
|
96
|
15.09 (5.17)
|
96
|
15.04 (4.99)
| | |
Post-treatment
|
53
|
9.79 (6.71)
|
54
|
11.76 (6.51)
|
− 2.18 (− 4.65 to 0.29)
|
0.08
|
Follow-up
|
61
|
7.16 (6.23)
|
63
|
10.29 (6.79)
|
− 2.91 (− 5.22 to − 0.60)
|
0.01
|
Days of these difficulties present
|
Pre-treatment
|
92
|
20.9 3 (9.61)
|
93
|
20.89 (8.51)
| | |
Post-treatment
|
66
|
13.98 (10.45)
|
67
|
18.10 (10.21)
|
− 3.93 (− 7.44 to − 0.43)
|
0.03
|
Follow-up
|
60
|
13.88 (11.17)
|
64
|
16.67 (9.59)
|
− 2.80 (− 6.40 to 0.80)
|
0.13
|
Days of total disability
|
Pre-treatment
|
91
|
11.22 (9.78)
|
92
|
10.82 (9.47)
| | |
Post-treatment
|
65
|
5.03 (7.15)
|
67
|
7.82 (9.03)
|
− 2.62 (− 5.29 to 0.06)
|
0.06
|
Follow-up
|
60
|
5.82 (7.34)
|
64
|
8.00 (7.82)
|
− 1.71 (− 4.46 to 1.03)
|
0.22
|
Days of activity reduce
|
Pre-treatment
|
90
|
14.14 (10.26)
|
92
|
12.97 (10.19)
| | |
Post-treatment
|
65
|
8.22 (8.40)
|
67
|
11.19 (9.58)
|
− 2.72 (− 5.92 to 0.49)
|
0.10
|
Follow-up
|
60
|
8.35 (9.57)
|
64
|
10.20 (9.69)
|
− 1.92 (− 5.22 to 1.38))
|
0.25
|
Perceived social support
|
Pre-treatment
|
96
|
51.92 (16.60)
|
96
|
52.74 (17.11)
| | |
Post-treatment
|
73
|
55.53 (17.70)
|
74
|
51.43 (18.03)
|
3.85 (− 4.55 to 9.25)
|
0.16
|
Follow-up
|
61
|
56.61 (17.35)
|
65
|
52.57 (14.70)
|
2.24 (− 3.42 to 7.90)
|
0.43
|
PSYCHLOPS
|
Pre-treatment
|
96
|
15.39 (3.65)
|
95
|
14.94 (3.77)
| | |
Post-treatment
|
67
|
9.31 (5.68)
|
69
|
11.55 (5.01)
|
− 2.40 (− 4.19 to − 0.60)
|
0.009
|
Follow-up
|
61
|
8.98 (5.93)
|
61
|
10.62 (4.99)
|
− 1.63 (− 3.51 to 0.24)
|
0.09
|